Cargando…

Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania

OBJECTIVE: To quantify preferences for preventive therapies for rheumatoid arthritis (RA) across three countries. METHODS: A web-based survey including a discrete choice experiment was administered to adults recruited via survey panels in the UK, Germany and Romania. Participants were asked to assum...

Descripción completa

Detalles Bibliográficos
Autores principales: Simons, Gwenda, Veldwijk, Jorien, DiSantostefano, Rachael L, Englbrecht, Matthias, Radawski, Christine, Bywall, Karin Schölin, Valor Méndez, Larissa, Hauber, Brett, Raza, Karim, Falahee, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891433/
https://www.ncbi.nlm.nih.gov/pubmed/36068022
http://dx.doi.org/10.1093/rheumatology/keac397
_version_ 1784881135000485888
author Simons, Gwenda
Veldwijk, Jorien
DiSantostefano, Rachael L
Englbrecht, Matthias
Radawski, Christine
Bywall, Karin Schölin
Valor Méndez, Larissa
Hauber, Brett
Raza, Karim
Falahee, Marie
author_facet Simons, Gwenda
Veldwijk, Jorien
DiSantostefano, Rachael L
Englbrecht, Matthias
Radawski, Christine
Bywall, Karin Schölin
Valor Méndez, Larissa
Hauber, Brett
Raza, Karim
Falahee, Marie
author_sort Simons, Gwenda
collection PubMed
description OBJECTIVE: To quantify preferences for preventive therapies for rheumatoid arthritis (RA) across three countries. METHODS: A web-based survey including a discrete choice experiment was administered to adults recruited via survey panels in the UK, Germany and Romania. Participants were asked to assume they were experiencing arthralgia and had a 60% chance of developing RA in the next 2 years and completed 15 choices between no treatment and two hypothetical preventive treatments. Treatments were defined by six attributes (effectiveness, risks and frequency/route of administration) with varying levels. Participants also completed a choice task with fixed profiles reflecting subjective estimates of candidate preventive treatments. Latent class models (LCMs) were conducted and the relative importance of attributes, benefit–risk trade-offs and predicted treatment uptake was subsequently calculated. RESULTS: Completed surveys from 2959 participants were included in the analysis. Most participants preferred treatment over no treatment and valued treatment effectiveness to reduce risk more than other attributes. A five-class LCM best fitted the data. Country, perceived risk of RA, health literacy and numeracy predicted class membership probability. Overall, the maximum acceptable risk for a 40% reduction in the chance of getting RA (60% to 20%) was 21.7%, 19.1% and 2.2% for mild side effects, serious infection and serious side effects, respectively. Predicted uptake of profiles reflecting candidate prevention therapies differed across classes. CONCLUSION: Effective preventive pharmacological treatments for RA were acceptable to most participants. The relative importance of treatment attributes and likely uptake of fixed treatment profiles were predicted by participant characteristics.
format Online
Article
Text
id pubmed-9891433
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-98914332023-02-02 Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania Simons, Gwenda Veldwijk, Jorien DiSantostefano, Rachael L Englbrecht, Matthias Radawski, Christine Bywall, Karin Schölin Valor Méndez, Larissa Hauber, Brett Raza, Karim Falahee, Marie Rheumatology (Oxford) Clinical Science OBJECTIVE: To quantify preferences for preventive therapies for rheumatoid arthritis (RA) across three countries. METHODS: A web-based survey including a discrete choice experiment was administered to adults recruited via survey panels in the UK, Germany and Romania. Participants were asked to assume they were experiencing arthralgia and had a 60% chance of developing RA in the next 2 years and completed 15 choices between no treatment and two hypothetical preventive treatments. Treatments were defined by six attributes (effectiveness, risks and frequency/route of administration) with varying levels. Participants also completed a choice task with fixed profiles reflecting subjective estimates of candidate preventive treatments. Latent class models (LCMs) were conducted and the relative importance of attributes, benefit–risk trade-offs and predicted treatment uptake was subsequently calculated. RESULTS: Completed surveys from 2959 participants were included in the analysis. Most participants preferred treatment over no treatment and valued treatment effectiveness to reduce risk more than other attributes. A five-class LCM best fitted the data. Country, perceived risk of RA, health literacy and numeracy predicted class membership probability. Overall, the maximum acceptable risk for a 40% reduction in the chance of getting RA (60% to 20%) was 21.7%, 19.1% and 2.2% for mild side effects, serious infection and serious side effects, respectively. Predicted uptake of profiles reflecting candidate prevention therapies differed across classes. CONCLUSION: Effective preventive pharmacological treatments for RA were acceptable to most participants. The relative importance of treatment attributes and likely uptake of fixed treatment profiles were predicted by participant characteristics. Oxford University Press 2022-09-07 /pmc/articles/PMC9891433/ /pubmed/36068022 http://dx.doi.org/10.1093/rheumatology/keac397 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Science
Simons, Gwenda
Veldwijk, Jorien
DiSantostefano, Rachael L
Englbrecht, Matthias
Radawski, Christine
Bywall, Karin Schölin
Valor Méndez, Larissa
Hauber, Brett
Raza, Karim
Falahee, Marie
Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania
title Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania
title_full Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania
title_fullStr Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania
title_full_unstemmed Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania
title_short Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania
title_sort preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the uk, germany and romania
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891433/
https://www.ncbi.nlm.nih.gov/pubmed/36068022
http://dx.doi.org/10.1093/rheumatology/keac397
work_keys_str_mv AT simonsgwenda preferencesforpreventivetreatmentsforrheumatoidarthritisdiscretechoicesurveyintheukgermanyandromania
AT veldwijkjorien preferencesforpreventivetreatmentsforrheumatoidarthritisdiscretechoicesurveyintheukgermanyandromania
AT disantostefanorachaell preferencesforpreventivetreatmentsforrheumatoidarthritisdiscretechoicesurveyintheukgermanyandromania
AT englbrechtmatthias preferencesforpreventivetreatmentsforrheumatoidarthritisdiscretechoicesurveyintheukgermanyandromania
AT radawskichristine preferencesforpreventivetreatmentsforrheumatoidarthritisdiscretechoicesurveyintheukgermanyandromania
AT bywallkarinscholin preferencesforpreventivetreatmentsforrheumatoidarthritisdiscretechoicesurveyintheukgermanyandromania
AT valormendezlarissa preferencesforpreventivetreatmentsforrheumatoidarthritisdiscretechoicesurveyintheukgermanyandromania
AT hauberbrett preferencesforpreventivetreatmentsforrheumatoidarthritisdiscretechoicesurveyintheukgermanyandromania
AT razakarim preferencesforpreventivetreatmentsforrheumatoidarthritisdiscretechoicesurveyintheukgermanyandromania
AT falaheemarie preferencesforpreventivetreatmentsforrheumatoidarthritisdiscretechoicesurveyintheukgermanyandromania